Medtronic (NYSE:MDT) today released 7-year follow-up data from a study of its 2-level Prestige LP cervical disc, touting favorable clinical outcomes and patient satisfaction with the system.
Medtronic (NYSE:MDT) today released 7-year follow-up data from a study of its 2-level Prestige LP cervical disc, touting favorable clinical outcomes and patient satisfaction with the system.